Razpipadon

Razpipadon
Clinical data
Other names	CVL-871; PF-06669571; PW-0464
Routes of; administration	By mouth
Drug class	Dopamine receptor agonist
Identifiers
	IUPAC name 6-[4-[3-(difluoromethoxy)pyridin-2-yl]oxy-2-methylphenyl]-1,5-dimethylpyrimidine-2,4-dione;
CAS Number	1643489-35-3;
PubChem CID	86764103;
ChemSpider	58945356;
UNII	6X6XF88J2M;
ChEMBL	ChEMBL3697578;
Chemical and physical data
Formula	C19H17F2N3O4
Molar mass	389.359 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC(=C1)OC2=C(C=CC=N2)OC(F)F)C3=C(C(=O)NC(=O)N3C)C;
	InChI InChI=1S/C19H17F2N3O4/c1-10-9-12(27-17-14(28-18(20)21)5-4-8-22-17)6-7-13(10)15-11(2)16(25)23-19(26)24(15)3/h4-9,18H,1-3H3,(H,23,25,26); Key:ZXIPVZWZRQCIRW-UHFFFAOYSA-N;

Razpipadon (developmental codes CVL-871, PF-06669571, and PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy.^[1]^[2]^[3]^[4] It is taken orally.^[1]

Quick Facts Clinical data, Other names ...

Razpipadon acts as a selective partial agonist of the dopamine D₁ and D₅ receptors.^[1]^[2]^[5] The drug has been found to increase willingness to exert effort for rewards in humans and hence appears to show pro-motivational effects.^[6]^[7]

The drug was originated by Pfizer and is under development by Cerevel Therapeutics.^[1] As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy.^[1]

See also